Amgen 2Q Revenues: $5.2 billion (+11%) 2Q Earnings: $1.5 billion (+26%) YTD Revenues: $9.7 billion (+9%) YTD Earnings: $2.6 billion (-35%) Comments: Enbrel sales increased 7% to $1.2 billion in the quarter. Kyprolis sales were $78 million (acquired from Onyx Pharmaceuticals acquisision in 4Q13). Prolia sales increased 40% to $264 million. XGEVA sales increased 20% to $299 million, despite generic competition. Combined Neulasta (pegfilgrastim) and NEUPOGEN (filgrastim) sales declined 1% to $...